Last €76.62 EUR
Change Today +0.29 / 0.38%
Volume 114.8K
SAN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 4:30 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Jean-Francois Dehecq

Honorary Chairman and President of The Sanofi Espoir Foundation, Sanofi
AgeTotal Calculated CompensationThis person is connected to 62 board members in 3 different organizations across 6 different industries.

See Board Relationships
74--

Background*

Mr. Jean-Francois Dehecq serves as the President of Sanofi-Synthélabo Daiichi Pharmaceuticals Co. Ltd. Mr. Dehecq serves as the President of The European Federation of Pharmaceutical Industries and Associations. He serves as a Director of Finance at Management (France), Financière Yves Rocher (France) and Laboratoires Daiichi Sanofi-Synthélabo (France). He served as the Chief Executive Officer of Sanofi-Aventis (formerly Sanofi-Synthélabo SA) since May 1999. Mr. Dehecq ...

Read Full Background

Corporate Headquarters*

54, Rue La Boétie
Paris, Ile-de-France 75008

France

Phone: 33 1 53 77 40 00
Fax: --

Board Members Memberships*

Former Director
Director
1995-Present
Independent Director, Chairman of Appointments Committee and Member of Audit Committee and Director of Air France
1999-2010
Honorary Chairman and President of The Sanofi Espoir Foundation
2006-N/A
Former Independent Director

Education*

Bachelor's Degree
Ecole Nationale Superieure d'Arts et Metiers

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €76.62 EUR +0.29

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.9M GBP
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.